Beijing's BeiGene out-licensed ex-China rights for tislelizumab, its anti-PD-1 antibody, to Novartis​​​ in a $2.2 billion agreement. The deal includes a $650 million upfront payment to BeiGene, plus up to $1.3 billion in regulatory milestones.